从脾肾虚论治原发性高血压的系统评价

Systematic review on treatment of essential hypertension from spleen and kidney deificency

目的:系统评价从脾肾虚论治原发性高血压的疗效和安全性。方法:采用电子和手工检索相结合的方式,全面检索近20年发表在国内医学期刊上的从脾肾虚来论治原发性高血压的中医药随机对照临床研究文献。利用Rev Man软件对多个研究结果的总体效应进行Meta分析,并进行敏感性分析;发表偏倚分析。结果:最终15项研究纳入本研究,共纳入患者1 661例。Meta分析降压疗效评价合并效应量RR(Random)及95%CI为:1.14[1.02,1.28];症状疗效评价合并效应量RR(Random)及95%CI为:1.34[1.16,1.55];纳入文献中试验组主要不良反应发生率为6.57%,对照组不良反应发生率为14.80%,安全性评价合并效应量RR(95%CI)为0.45[0.27,0.76]。结论:从脾肾虚来论治原发性高血压疗效确切安全性较高。

Objective：To evaluate the efficacy and safety of essential hypertension（EH） treated in light of the pathogenesis of spleen and kidney deificiency.Methods：Electronic retrieval databases and manual search were used.A comprehensive search for nearly 20 years medical journals published in China from the spleen and kidney deficiency on the treatment of EH to randomized controlled clinical study of Chinese medicine literature.By means of Rev Man software,the overall effect of results from multiple studies was analyzed by Meta-analysis.Meanwhile,a sensitivity analysis was also done.A funnel plot was applied to analyze the publication bias.Results：The final 15 studies included in this study including a total of 1661 cases of patients.Meta analysis of combined effects of antihypertensive efficacy evaluation of the amount RR（Random）,and 95% CI：1.14 [1.02,1.28].Clinical evaluation of symptoms combined effect size RR（Random）,and 95% CI：1.34 [1.16,1.55].In literature,the main test group was 6.57% adverse events,adverse events in the control group was 14.80%,the safety evaluation of combined effect size RR（95% CI） was 0.45 [0.27,0.76].Conclusion：Treatment of EH from the spleen and kidney deficiency were effective,and the level of safety is reliable.